LHLars Hagmeyer

Lars Hagmeyer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lars Hagmeyer has a total of 313 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Progression-survival dissociation in connective tissue disease (CTD)-associated interstitial lung disease (ILD): CTD-ILD versus non-CTD ILD in real-world practice

    by Jürgen Behr, Francesco Bonella, Andreas Günther, Michael Kreuter, David Pittrow, Benjamin Seeliger, Antje Prasse, Christine Pausch, Dirk Skowasch, Heinrike Wilkens, et al.

    Background: Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a clinically relevant subtype of fibrotic ILD. We compared baseline characteristics, treatment patterns, transplant-free survival (TFS) and progression-free survival (PFS) between CTD-ILD and non-CTD ILD. Methods: In the prospective German INSIGHTS-ILD registry, patients with known CTD status at baseline were classified as CTD-ILD or non-CTD ILD. TFS and PFS were analysed using Kaplan–Meier and log-rank tests. PFS was defined by a prespecified composite end-point including lung function decline, oxygen escalation, 6-min walk distance decline, respiratory hospitalisation, death or clinical worsening prompting any medical therapy escalation or switch. Cox models included the unadjusted Model A; Model B adjusted for age, sex, smoking, comorbidity count and baseline antifibrotic therapy; Model C additionally adjusted for baseline forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide; and Model D additionally adjusted for time since diagnosis. Results: 332 patients (35.7%) had CTD-ILD and 598 (64.3%) had non-CTD ILD. Patients with CTD-ILD were younger, more often female and more frequently received immunomodulatory therapy, whereas antifibrotic use was similar between groups. TFS was similar at 1 year (90.8% versus 90.9%; p=0.57) and at 2 years (83.7% versus 81.9%). In contrast, PFS was higher in CTD-ILD at 1 year (71.8% versus 62.7%; p=0.0032) and 2 years (52.6% versus 41.7%), with less FVC decline over follow-up. CTD-ILD was associated with a lower risk of progression in the unadjusted model (HR 0.73, 95% CI 0.59–0.90; p=0.003) and across all adjusted models. Conclusion: In routine care, CTD-ILD showed similar TFS but better PFS and less FVC decline than non-CTD ILD.

  • Open Access

    Sex-Specific Phenotypes and Outcomes in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease: Results from the INSIGHTS-ILD Registry

    by Dirk Koschel, Francesco Bonella, Andreas Günther, Michael Kreuter, David Pittrow, Benjamin Seeliger, Christine Pausch, Dirk Skowasch, Heinrike Wilkens, Hubert Wirtz, et al.

    Introduction: Sex-related differences in interstitial lung disease (ILD) phenotypes are well recognized, but it remains unclear whether sex itself independently influences outcomes in non-idiopathic pulmonary fibrosis (non-IPF) ILD once comorbidities, lung function, and treatment are considered. Methods: In the prospective INSIGHTS-ILD registry (data cut 17 September 2025), we compared men and women with non-IPF ILD using descriptive analyses and Cox models with prespecified adjustment steps: model A (age, comorbidity count, and smoking), model B (A + forced vital capacity [FVC] and diffusing capacity of the lung for carbon monoxide [DLCO]), and model C (B + antifibrotic therapy). Prespecified subgroup analyses included age strata (≤55 and >55 years) and ILD entities. Longitudinal FVC and DLCO trajectories were assessed over 24 months. Results: Among 883 patients (483 men and 400 women), exposures and disease entities differed significantly by sex: men reported more occupational/environmental exposures and had higher rates of fibrotic idiopathic interstitial pneumonia, whereas women more frequently had autoimmune-related ILD and a family history of ILD. Men had a higher comorbidity burden and more often received antifibrotic therapy at baseline. Survival was shorter in men (HR: 1.51; 95% CI: 1.03–2.21), but this association disappeared after adjustment in model A (HR: 1.04; 95% CI: 0.65–1.68), model B (HR: 1.03; 95% CI: 0.61–1.74), and model C (HR: 1.04; 95% CI: 0.62–1.77). Progression-free survival and transplant-free survival showed no consistent sex-related differences. Longitudinal FVC and DLCO declines were modest and largely parallel in both sexes, with no significant between-group differences. Findings were similar across age groups and ILD entities. Conclusion: Men and women with non-IPF ILD differ in exposures, phenotypes, and comorbidities, but after accounting for these factors, sex is not an independent predictor of survival or functional progression. Risk assessment should therefore primarily be based on objective disease characteristics rather than sex alone.


  • A Systematic Review of the Safety of Sedation during Flexible Bronchoscopy

    by Sandhya Matthes, Marcel Treml, Ralf-Harto Hübner, Jürgen Hetzel, Ralf Eberhardt, Karl-Josef Franke, Felix J. Herth, Angélique Holland, Torsten Loop, Helmut Sitter, et al.

    Introduction: Sedation during flexible bronchoscopy can be administered by a second physician, an anesthesiologist or as nurse-administered sedation (NAS). Propofol is often administered by non-anesthesiologists. It is unclear whether complications differ with various sedation protocols. Methods: We searched PubMed for clinical trials of sedation during bronchoscopy and conducted a systematic review of complications (death ≤24 h post-procedure or intensive care unit (ICU) admission/predefined cardiopulmonary escalation [CPE]). Outcomes were analyzed according to the staff administering sedation, complexity of procedure, for propofol-containing regimes, and the ASA physical status classification of the patient. Results: This analysis (120 articles, 39,475 procedures) showed a mortality rate of 0.01% for sedation bronchoscopy. ICU admission rate was 0.12%, and CPE was reported in 0.57%. Significantly higher CPE was recorded for anesthesiologists compared to NAS and second physicians (1.16% vs. 0.65% vs. 0.07%, respectively, p < 0.001) with higher ICU admission for NAS compared to anesthesiologists and second physicians (0.35% vs. 0.00% vs. 0.03%, respectively, p < 0.001). Endobronchial ultrasound did not increase complication rates. Admission to ICU and CPE remained <1% in propofol-containing regimes, although complications were slightly lower without propofol. Comparison of lower risk ASA 1–2 studies compared to studies with ASA 1–3 showed no significant difference in outcome. Conclusion: Sedation bronchoscopy is a safe procedure. The staff administering sedation may react differently to periprocedural respiratory and cardiovascular events. Propofol application is not associated with a clinically relevant increase in complication rate. There is no evidence that ASA status is a predictor of individual risk at bronchoscopy.


  • Open Access

    Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysis

    by Jürgen Behr, Antje Prasse, Hubert Wirtz, Dirk Koschel, David Pittrow, Matthias Held, Jens Klotsche, Stefan Andreas, Martin Claussen, Christian Grohé, et al.

    Introduction: Idiopathic pulmonary fibrosis (IPF) has high morbidity and mortality with limited treatment options. Goal-oriented management approaches, such as the “treatable traits” concept, have yet to be implemented in IPF. This study aims to identify specific treatment goals in IPF for potential interventions by analysing outcomes from two national registries. Methods: We used data from the INSIGHTS-IPF registry, comprising 1232 IPF patients, enrolled from 2014 to 2020 as derivation cohort. Baseline and 6-month follow-up data were examined to assess clinical progression and predict 1-year mortality. Variables included forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide ( D LCO ), 6-min walk distance (6MWD), body mass index (BMI) and comorbidities. For validation we used data from 490 IPF patients enrolled in the Canadian Registry for Pulmonary Fibrosis (CARE-PF) and the full 2576 fibrotic interstitial lung disease (ILD) cohort of the CARE-PF registry. Results: Multivariable analysis identified FVC, D LCO , 6MWD and BMI as independent predictors of 1-year survival. We established three risk groups based on these variables: low risk (30%). Potential treatment goals were defined based on FVC, D LCO , 6MWD and BMI, which are readily available and may be responsive to interventions. Our risk model showed equivalent accuracy in the validation cohort, both for IPF alone and the overall population. Conclusion: This study provides a novel risk model for IPF patients, which may also apply to a broader spectrum of fibrotic ILD. It is based on potentially actionable variables which deserve further evaluation as measurable treatment goals in interventional clinical trials.


  • Maligne zentrale Atemwegsstenosen: Prädiktive Faktoren für den klinischen Benefit einer therapeutischen Bronchoskopie

    by Lars Hagmeyer

    Introduction: Therapeutic bronchoscopy (TB) is considered a safe and effective treatment for patients withmalignant central airway obstruction (MCAO). While many factors have been associated with technical success, it does not always translate in clinical success. Few factors to predict clinical response have been described. The objective of this study was to determine predictive factors of clinical success for patients with MCAO undergoing TB. Methods: We used the multicenter prospective registry EpiGETIF to collect data from patients with MCAO undergoing TB from January 2019 to June 2021. The criterion for clinical success was dyspnea measured on the Borg scale. Patients were classified as super responders if they had an improvement of 4 points after the procedure. Uni- and multivariate analysis were performed to highlight an association between preprocedural features and clinical success. Results: 496 patients from 24 centers met inclusion criteria. The mean preprocedural Borg score was 6.5 ± 2.0 versus 2.2 ± 1.7 postprocedural (mean difference 4.3 ± 2.3). 302 patients (60.9%) were considered super responders. The only factor associated with super responders in multivariate analysis was a higher baseline Borg score. The only factor associated with non-super responders was a poor performance status and mechanical ventilation.

  • Open Access

    Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry

    by Jürgen Behr, Michael Kreuter, Andreas U. Guenther, Francesco Bonella, David Pittrow, Christine Pausch, Benjamin Seeliger, Antje Prasse, Dirk Skowasch, Henrike Wilkens, et al.

    Background: This study aims to report real-life data on the characteristics and treatment patterns of patients with fibrosing interstitial lung disease (ILD; except idiopathic pulmonary fibrosis) across multiple specialised centres in Germany. Eligibility criteria included ILD affecting >10% of lung parenchyma on high-resolution computed tomography, a single breath diffusion capacity for carbon monoxide (DLCO) ≤80% predicted and active treatment of lung disease.Methods: As of the interim analysis cut-off, 655 patients (mean±sdage 65.9±11.7 years, 54.5% male) were included. The most common ILD subtypes were fibrosing hypersensitivity pneumonitis (31.2%), fibrosing ILD (22.0%), rheumatoid arthritis and connective tissue disease ILDs (13.0%) and unclassifiable fibrosing ILD (13.0%).Results: Lung function metrics included total lung capacity at 68.3±17.6% predicted, forced vital capacity at 69.8±19.8% predicted, forced expiratory volume in 1 s at 73.7±19.5% predicted andDLCOat 33.8±15.6% predicted. Current treatments included oral steroids (62.6%), antifibrotic therapy (50.7%), azathioprine (14.4%), methotrexate (10.2%) and mycophenolate mofetil (11.1%). Patients on antifibrotic therapy were typically older at diagnosis and registry inclusion, more often male, had more comorbidities, a lower 6-min walk distance and reduced lung function metrics compared with those not on antifibrotic therapy. Notably, 27.3% of the patients on antifibrotic therapy did not meet progression criteria (INBUILD), whereas 40.1% of patients not receiving antifibrotic therapy did meet those criteria.Conclusion: The patient characteristics observed align with those observed in randomised controlled trials and other noninterventional studies. Patients on antifibrotic therapy generally had more severe disease profiles.


  • Versorgungsrealität der Bronchoskopie in Deutschland – eine Umfrage der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)

    by Kyrill Boschung, Jürgen Hetzel, Ralf-Harto Hübner, Frank Pohl, Marcel Treml, Kaid Darwiche, Ralf Eberhardt, Angelique Holland, Torsten Bauer, Winfried Randerath, et al.

    Zusammenfassung: Ziel Aufgrund technischer Innovationen und des gesundheitsökonomischen Drucks hat sich die Bronchoskopie in den letzten Jahren deutlich gewandelt. Es gibt wenig aktuelle Informationen zur Versorgungsrealität in der Bronchoskopie in Deutschland. Methodik Im September 2022 wurden die bronchoskopisch tätigen Standorte in einer anonymisierten Erhebung der DGP mit 33 Fragen systematisch zu Merkmalen der Struktur- und Prozessqualität befragt. Die erhobenen Daten wurden deskriptiv ausgewertet. Ergebnisse Von 196 teilnehmenden wurden an 180 Standorten regelmäßig Bronchoskopien durchgeführt. Ein Großteil der Standorte sind Krankenhäuser der Grund- und Regelversorgung (n=51) sowie Maximalversorger (n=43) (Leistungsspektrum: diagnostische Bronchoskopie, 80% inklusive der endobronchialen ultraschallgesteuerten transbronchialen Nadelaspiration [EBUS-TBNA]). Für den Akutfall sind erweiterte Behandlungsmöglichkeiten an >90% dieser Standorte sichergestellt. Universitätskliniken (n=24) und Lungenfachkliniken (n=35) erbringen darüber hinaus aufwendigere diagnostische Verfahren sowie therapeutisch-interventionelle Techniken. Dabei sind die Leistungszahlen an den Lungenfachkliniken signifikant höher (Lungenfachkliniken: 62%: >2000 Bronchoskopien/Jahr; Unikliniken: 25%: >2000 Bronchoskopien/Jahr; p2 klassifizierten Patienten ziehen 46% der klinischen Standorte einen zweiten Arzt hinzu, 47% der Standorte bei einer ASA-Klassifikation >3. Schlussfolgerung Ein Großteil der Bronchoskopien wird von pneumologischen Abteilungen an Krankenhäusern der Grund- und Regelversorgung sowie der Maximalversorgung durchgeführt. Für aufwendigere Verfahren ist die Kooperation mit Kliniken mit ausgewiesenem Schwerpunkt im Bereich der Bronchologie und Interventionellen Pneumologie, wie er häufig an Universitätskliniken oder Lungenfachkliniken angeboten wird, sinnvoll.


  • Empfehlungen zu Trainingskursen in der Bronchoskopie – Update 2024

    by Lars Hagmeyer, Ralf-Harto Hübner, Kaid Darwiche, Ralf Eberhardt, Andreas Gebhardt, Felix Herth, Angelique Holland, Joanna Krist, Carmen Pizarro, Gregor Zimmermann, et al.

    Zusammenfassung: Bronchoskopiekurse sollten einen festen Bestandteil der bronchoskopischen Ausbildung darstellen. Kursabsolventen sollen nach dem Bronchoskopiekurs mit den Indikationsfeldern, Voraussetzungen und technischen Möglichkeiten der Bronchoskopie vertraut sein. Neben theoretischen Inhalten werden in Kleingruppen am Bronchoskopiemodell unter Supervision praktische bronchoskopische Fertigkeiten vermittelt und am Simulationsmodell trainiert. Die Grundlage der vermittelten Inhalte sind dabei die aktuellen Leitlinien und Empfehlungen der DGP sowie die geltenden Richtlinien und KRINKO-Empfehlungen. Die Vereinheitlichung zentraler Kurselemente dient der flächendeckenden Qualitätssicherung, dennoch sollen lokale standortspezifische Schwerpunktsetzungen explizit unterstützt werden.


  • Open Access

    Sedierung für Bronchoskopie: Optimal dosierte HFNC-Oxygenierung kann Desaturationen verhindern

    by Lars Hagmeyer

    Obwohl die Anwendung einer High-Flow-Nasenkanüle (HFNC) derzeit empfohlen wird, um während der Sedierung bei einer Bronchoskopie eine Sauerstoffentsättigung zu verhindern, besteht noch kein Konsens über die optimale Flussrate. Ziel dieser prospektiven, randomisierten und kontrollierten Stu­die war es, die optimale Sauerstoffflussrate für die HFNC zu bestimmen, um eine Entsättigung während der Sedierung bei einer Bronchoskopie effektiv zu vermeiden. Insgesamt wurden 240 Patienten, bei denen eine Bronchoskopie geplant war, randomisiert und erhielten HFNC in Kombination mit Propofol-Sedierung (mit 100% Sauerstoff) bei einer von sechs verschiedenen Flussraten von 10, 20, 30, 40, 50 und 60 l/min, die in den Gruppen 1–6 eingeteilt wurden. Die Ergebnisse zeigten, dass die Häufigkeit der Entsättigung mit zunehmender Sauerstoffflussrate signifikant abnahm (42,5%, 17,5%, 15%, 10%, 2,5% bzw. 0% in den Gruppen 1–6, p < 0,0001). Die mittels Probit-Regression berechnete optimale Sauerstoffflussrate zur Vermeidung einer Entsättigung bei 95% der Patien­ten lag bei 43,20 l/min (95%-Konfidenzintervall, 36,43–55,96 l/min). Eine Erhöhung der Sauerstoffflussrate reduzierte deutlich die Notwendigkeit von Atemwegsinterventionen. Auf Basis dieser Ergebnisse wird eine HFNC-Flussrate von 50–60 l/min empfohlen, um eine Entsättigung während der Sedierung bei einer Bronchoskopie effektiv zu verhindern.

  • Open Access

    Closing the RCT Gap—A Large Meta-Analysis on the Role of Surgery in Stage I–III Small Cell Lung Cancer Patients

    by Fabian Doerr, Sebastian Stange, Sophie Salamon, Konstantinos Grapatsas, Natalie Baldes, Maximilian Michel, Hruy Menghesha, Georg Schlachtenberger, Matthias B. Heldwein, Lars Hagmeyer, et al.

    Introduction: Despite clear guideline recommendations, surgery is not consistently carried out as part of multimodal therapy in stage I small cell lung cancer (SCLC) patients. The role of surgery in stages II and III is even more controversial. In the absence of current randomized control trials (RCT), we performed a meta-analysis comparing surgery versus non-surgical treatment in stage I to III SCLC patients. Methods: A systematic review of the literature was conducted on 1 July 2023, focusing on studies pertaining to the impact of surgery on small cell lung cancer (SCLC). These studies were evaluated using the ROBINS-I tool. Statistical analyses, including I² tests, Q-statistics, DerSimonian-Laird tests, and Egger regression, were performed to assess the data. In addition, 5-year survival rates were analyzed. The meta-analysis was conducted according to PRISMA standards. Results: Among the 6826 records identified, 10 original studies encompassing a collective cohort of 95,323 patients were incorporated into this meta-analysis. Heterogeneity was observed across the included studies, with no discernible indication of publication bias. Analysis of patient characteristics revealed no significant differences between the two groups (p-value > 0.05). The 5-year survival rates in a combined analysis of patients in stages I–III were 39.6 ± 15.3% for the ‘surgery group’ and 16.7 ± 12.7% for the ‘non-surgery group’ (p-value < 0.0001). SCLC patients in stages II and III treated outside the guideline with surgery had a significantly better 5-year survival compared to non-surgery controls (36.3 ± 20.2% vs. 20.2 ± 17.0%; p-value = 0.043). Conclusions: In the absence of current RCTs, this meta-analysis provides robust suggestions that surgery might significantly improve survival in all SCLC stages. Non-surgical therapy could lead to a shortening of life. The feasibility of surgery in non-metastatic SCLC should always be evaluated as part of a multimodal treatment.